enGene Therapeutics (ENGN) Non-Current Debt (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Non-Current Debt of $24.9 million for Q2 2026, up 24.41% year-over-year from $20.0 million in Q2 2025, and up 0.7% quarter-over-quarter from $24.7 million in Q1 2026.
enGene Therapeutics (ENGN) Non-Current Debt (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Non-Current Debt for 5 consecutive years, with $24.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Debt rose 24.41% year-over-year to $24.9 million; the TTM figure through Apr 2026 stood at $24.9 million (up 24.41% YoY), while the FY2025 annual figure was $15.3 million, down 31.81% from the prior year.
- Non-Current Debt grew to $24.9 million in Q2 2026 per ENGN's latest filing, from $24.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $24.9 million in Q2 2026 and bottomed at $9.2 million in Q4 2023.
- Historically, Non-Current Debt has averaged $19.4 million across 5 years, with a median of $21.7 million in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Debt jumped 143.85% — and 2025, when it tumbled 31.81%.
- enGene Therapeutics' Non-Current Debt stood at $9.6 million in 2022, then fell by 4.49% to $9.2 million in 2023, then surged by 143.85% to $22.5 million in 2024, then sank by 31.81% to $15.3 million in 2025, then jumped by 62.56% to $24.9 million in 2026.
- Business Quant data shows ENGN's Non-Current Debt at $24.9 million in Q2 2026, $24.7 million in Q1 2026, and $15.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 24.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 24.91 Mn |
| Jan 31, 2026 | 24.74 Mn |
| Oct 31, 2025 | 15.32 Mn |
| Jul 31, 2025 | 17.71 Mn |
| Apr 30, 2025 | 20.02 Mn |
| Jan 31, 2025 | 21.70 Mn |
| Oct 31, 2024 | 22.47 Mn |
| Jul 31, 2024 | 21.61 Mn |
| Apr 30, 2024 | 22.73 Mn |
| Jan 31, 2024 | 22.53 Mn |
| Oct 31, 2023 | 9.22 Mn |
| Oct 31, 2022 | 9.65 Mn |